Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: A serial echocardiographic study  by Blanchard, Daniel G. et al.
1270 JACC Vol. 17, No.6 
May 1991:1270-6 
Reversibility of Cardiac Abnormalities in Human Immunodeficiency 
Virus (HIV)-Infected Individuals: A Serial Echocardiographic Study 
DANIEL G. BLANCHARD, MD, CAROL HAGENHOFF, RN, MPH, LEON C. CHOW, MD, FACC, 
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Seventy adults who tested positive for human immunodeficiency 
virus (HIV) were prospectively studied with serial echocardiog-
raphy to better define the prevalence and progression of cardiac 
disease in such patients. Fifty outpatients (Group A), including 44 
with acquired immunodeficiency syndrome (AIDS) and 6 with 
AIDS-related complex, and 20 additional patients (Group B) with 
asymptomatic HIV infection had baseline echocardiographic stud-
ies at a time when no patient had symptomatic heart disease. 
Follow-up studies were performed at 9 ± 3 months in 52 patients 
(74 %) and again at 15 ± 3 months after baseline studies in 29 
patients (41 %). During the study, 22 patients (44%) in Group A 
and 1 patient (5%) in Group B died. 
Cardiac abnormalities were noted in 26 patients (52 %) in 
Group A and 8 patients (40%) in Group B (p = NS) on initial or 
follow-up study. An abnormal left ventricular ejection fraction 
«45 %) or fractional shortening «28 %) was seen in seven 
patients in Group A; of these, three had normal left ventricular 
function on a later echocardiogram. One patient in Group B had 
persistent left ventricular dysfunction. All patients in Group A 
with left ventricular dysfunction on two serial studies died within 
1 year after the initial echocardiogram. Ejection fraction did not 
Several groups (1-22) have described the occurrence of 
human immunodeficiency virus (HIY)-associated cardiac 
abnormalities in both pathologic and clinical studies. These 
studies report a widely variable prevalence of cardiac lesions 
among patients infected with HIY, depending on the patient 
group selected and the methods used. Studies (6,7,14) of 
patients with asymptomatic HIY infection note a relatively 
low frequency of left ventricular dysfunction and other 
abnormalities, while many autopsy studies (2-4,15) in pa-
tients with the acquired immunodeficiency syndrome (AIDS) 
report higher percentages of cardiac lesions, including lym-
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change between baseline and two follow-up studies in either group 
(A: 52 ± 9 vs. 56 ± 9 vs. 55 ± 5%, p = NS; B: 58 ± 6 vs. 58 ± 
5 vs. 59 ± 6%, p = NS). Right-sided cardiac enlargement resolved 
in 18 patients (44 %), including 5 of 10 in Group A and 3 of 8 in 
Group B. Pericardial effusions resolved without specific interven-
tion in 5 (42%) of 12 patients in Group A and 2 (50%) of 4 in 
Group B. Analysis of CD4 counts revealed no relation with the 
presence of left ventricular dysfunction or right-sided cardiac 
enlargement. In patients with AIDS with pericardial effusion, 
however, CD4 counts were significantly lower (68 ± 74/mm3) than 
in those without effusion (290 ± 248/mm3 , p < 0.001). 
Thus, echocardiographic abnormalities are common in asymp-
tomatic outpatients with HIV infection, and persistent left ven-
tricular dysfunction portends an especially grim prognosis in 
patients with AIDS. Some of these abnormalities, including left 
ventricular dysfunction, right-sided cardiac enlargement and 
pericardial effusion, are transient in nature and are not consis-
tently associated with clinically apparent intercurrent illnesses. 
These findings have important implications for future studies 
involving therapy for AIDS-associated heart disease. 
(J Am Call CardioI1991;17:1270-6) 
phocytic myocarditis, left ventricular enlargement, cardiac 
Kaposi's sarcoma and myocardial fibrosis. Recent echocar-
diographic studies (6,7,9, 11,14,22) found abnormalities, in-
cluding pericardial effusion, biventricular enlargement and 
dysfunction, cardiac masses and mitral valve prolapse, in 0% 
to 70% of various patient groups. No serial studies are 
available, however, to assess the progression of HIY-
associated cardiac disease in adults. Therefore, we prospec-
tively studied groups of HIY-infected individuals with serial 
echocardiography to better define the prevalence of cardiac 
lesions in these patients and, more important, to assess the 
evolution of these abnormalities. 
Methods 
Study patients. The study included 70 patients (69 men, 1 
woman) with HIY who were enrolled consecutively between 
January 1987 and June 1989. Patients were enrolled if they 
were willing to participate in the study and were ambulatory 
outpatients. None of those enrolled were intravenous drug 
abusers, although such patients were not excluded from the 
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study. Mean patient age (±SD) was 38.1 ± 9.3 years (range 
24 to 64). The patients were divided into two groups: Group 
A consisted of 50 patients with AIDS (n = 44) or AIDS-
related complex (n = 6); Group B consisted of 20 patients 
with asymptomatic HIV infection. No patient had sympto-
matic heart disease at the beginning of the study, and all 
patients were followed up by the California Cooperative 
Treatment Group at the University of California, San Diego. 
All patients in Group A were being treated with the antiret-
roviral drug azidothymidine (or zidovudine, AZT) except 
three who were enrolled in 1987 and died before 1988. The 
majority of Group B patients were taking AZT during the 
study period: 11 were taking AZT, 8 were taking AZT or a 
placebo (this protocol code has not yet been broken), and 1 
patient was lost to follow-up. 
Study protocol. The study protocol consisted of baseline 
echocardiography and follow-up echocardiography, at ::::6 
month intervals, as approved in 1986 by the Human Subjects 
Committee at the University of California, San Diego. 
The hospital and protocol charts of all patients were 
analyzed for height and weight at initial evaluation, drugs 
and other intervention (for example, pericardiocentesis), 
protocol (if available), illness during the study period, cause 
and date of death (if applicable) and serial CD4 counts. CD4, 
previously known as T4, is a T lymphocyte antigenic marker 
recognized to correlate with prognosis and susceptibility to 
opportunistic infections in individuals with HIV (23). In the 
University of California, San Diego immunology laboratory, 
the CD4 count for normal patients ranges from 500/mm3 to 
I,200/mm3 . 
Echocardiography. Quantitative M-mode. two-dimen-
sional and Doppler echocardiograms were performed on a 
Hewlett-Packard Sonos 500 or 1000 ultrasound instrument. 
Standard views in the supine or left lateral decubitus position 
were obtained. Variables analyzed included left ventricular 
end-diastolic and end-systolic diameter, fractional shorten-
ing and left atrial size on M-mode, as well as left ventricular 
end-diastolic and end-systolic areas and right ventricular 
end-diastolic area on two-dimensional echocardiography. 
The echocardiograms were also reviewed for the presence of 
left and right atrial enlargement, valvular vegetations and 
abnormalities, mitral valve prolapse (defined as prolapse of 
either mitral valve leaflet behind the level of the mitral 
anulus on parasternal, long-axis view) (24), pericardial effu-
sions and intracardiac masses. 
End-diastolic and end-systolic areas of the left ventricle, 
as well as the end-diastolic area of the right ventricle, were 
digitized on a computer grid in the apical four-chamber view. 
Left ventricular volumes and ejection fraction were calcu-
lated by an off-line analysis system that utilizes a modified 
Simpson's rule (25,26). Volumes were corrected for body 
surface area. In our study the lower limit of normal value 
was 45% for ejection fraction and 28% for fractional short-
ening. These limits. similar to those in a previous study (14), 
were chosen to avoid labeling borderline normal values as 
abnormal. A normal value for right ventricular area was 
Table 1. Patients With Cardiac Abnormalities on Any Study 
Group A Group B Total 
(n = 50) (n = 20) (70) 
Any abnormality 26 (52%) 8 (40%) 34 (49%) 
Mitral valve prolapse (MVP) 5 (10%) 2 (10%) 7 (10%) 
Excluding MVP as sole 24 (48%) 7 (35%) 31 (44%) 
abnormality 
Left ventricular dysfunction 7 (14%) 1 (5%) 8 (11%) 
(EF <459t. FS <289t) 
Right-sided cardiac 10 (20%) 7 (35%) 17 (24%) 
enlargement 
Pericardial effusion 11 (22%) 4 (20%) 15 (21%) 
Data are expressed as number and. in parentheses, percent of patients 
with an abnormality. EF = ejection fraction; FS = fractional shortening; 
Group A = 44 patients with acquired immunodeficiency syndrome (AIDS) and 
6 patients with AIDS-related complex; Group B = 20 patients with asympto-
matic HIV infection. 
defined as 12 to 26 cm2 (27) and a normal value for left 
ventricular end-diastolic volume index as <80 mllm2 (26). To 
assess inter- and intraobserver variability, 10% of echocar-
diograms were chosen randomly and reanalyzed by two of 
the investigators. 
Statistical analysis. Data were evaluated by chi-square 
test. Fisher's exact test and Student's t test. Comparisons 
were made between Groups A and B (patients with AIDS 
and AIDS-related complex vs. those with asymptomatic 
HIV infection). Data are mean values ± SD. Differences 
between groups were considered significant at p < 0.05. 
Results 
Clinical course. Of the 70 initial patients. 52 (33 in Group 
A and 19 in Group B) had follow-up echocardiographic 
studies (the mean interval between studies was 9 ± 3 
months, range 6 to 16 months). Between the baseline and 
first follow-up studies, 22% of patients in Group A died, and 
12% were lost to follow-up. In Group B, 5% of patients were 
lost to follow-up. A second follow-up study was done in 29 
patients (18 in Group A, 11 in Group B) at a mean interval of 
15 ± 3 months (range 12 to 21) after the baseline study. 
Between the first and second follow-up echocardiograms, an 
additional 22% of Group A patients died and 8% were lost to 
follow-up. In Group B, 5% of the patients died and 35% were 
either lost to follow-up or have studies pending at this time. 
Echocardiographic abnormalities (Table 1). Overall. 
echocardiographic abnormalities were identified in 49% of 
patients on one or more studies (52% in Group A and 40% in 
Group B). Mitral valve prolapse was noted in five Group A 
patients 00%) and two Group B patients (10%). Excluding 
those patients whose only echocardiographic lesion was 
mitral valve prolapse, abnormalities were present in 44% of 
all patients (48% of patients in Group A and 35% in Group 
B). 
Group A (Fig. 1). Mean ejection fraction did not change 
significantly between studies (52 ± 9% vs. 56 ± 9% vs. 55 ± 
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5%, p = NS). Left ventricular end-diastolic volume index 
also did not change significantly (57 ± 12 vs. 54 ± 14 vs. 56 
± 18 mllm2, p = NS). An abnormal left ventricular ejection 
fraction or fractional shortening was initially seen in 6 of 33 
patients with serial studies, but in only 3 of those 6 at 
follow-up study (Fig. lA). One patient with an initially 
normal ejection fraction had new global hypokinesia and an 
ejection fraction of 44% on the second follow-up study. 
While most patients with a low ejection fraction were in poor 
health, none were limited by congestive heart failure symp-
toms as such and none required medical therapy for cardiac 
symptoms. Of the seven patients with left ventricular dys-
function in Group A, three had a normal left ventricular 
ejection fraction documented on a subsequent echocardio-
gram. All three patients with persistently abnormal left 
ventricular function on serial echocardiograms died within I 
year after the baseline study. 
Seven patients in Group A had right-sided cardiac en-
largement initially (Fig. IB). The first follow-up study 
showed resolution of this abnormality in four of these seven, 
while two new cases of right ventricular enlargement were 
found. On the second follow-up study, one new case of right 
ventricular enlargement was present. Of the five patients 
with right ventricular enlargement ~n the first follow-up 
study. one had resolution of the abnormality, one was lost to 
follow-up and three died before the final examination. Of the 
10 patients with right-sided cardiac enlargement in Group A, 
5 (50%) had normal right heart size on a subsequent study. 
Review of all available patient charts revealed that four 
Group A patients had Pneumocystis carinii pneumonia di-
agnosed within I month before or after an echocardiogram 
that demonstrated right ventricular enlargement. In addition, 
three of these patients had normal right ventricular size on 
subsequent studies after the pneumonia was treated. How-
ever, the remaining six patients with right ventricular en-
largement had no documented pulmonary infection at or 
near the time of echocardiography. 
Pericardial effusion was found initially in six Group A 
patients. but in only one of the six on follow-up study. None 
of the initial effusions were associated with cardiac tampon-
ade, and none of these patients underwent pericardiocente-
sis. Five new effusions were seen on the first follow-up 
study. including two in patients with echocardiographic 
evidence of impending cardiac tamponade (right atrial and 
right ventricular diastolic collapse). One of these patients 
underwent pericardiocentesis with immediate improvement 
in right ventricular filling; both patients later died before a 
second follow-up study was performed. A review of patient 
charts showed an intercurrent febrile illness associated with 
a pericardial effusion in one patient and an episode of 
asymptomatic left ventricular enlargement in another. In the 
remaining patients with pericardial effusion. no significant 
intercurrent illnesses were noted. Of the six patients with 
effusion on the first follow-up study. four died before a 
second follow-up echocardiogram, and the remaining two 
had persistent effusion on the final studies. No effusions 
were large at baseline or showed evidence of tamponade. 
Without specific treatment, 5 (42%) of 12 pericardial effu-
sions in Group A resolved by the time of a later echocardio-
gram. 
Group B (Fig. 2). Mean left ventricular ejection fraction 
did not change between studies (58 ± 6% vs. 58 ± 5% vs. 59 
± 6%, p = NS), and no patient had an ejection fraction 
<45% (Fig. 2A). Serial left ventricular end-diastolic volume 
indexes were also similar among studies (50 ± 6 vs. 53 ± 15 
vs. 52 ± 10 mllm2, p = NS). One patient had evidence on the 
initial study of left ventricular dysfunction (fractional short-
ening 14%) that persisted on follow-up study, although serial 
ejection fractions were in the normal range (47% and 49%). 
One Group B patient had right ventricular enlargement at 
baseline that resolved by the time of the first follow-up 
study, but five other patients had right ventricular enlarge-
ment at that time (Fig. 2B). Of these five, one developed 
AIDS and later died (the same patient who also developed a 
pericardial effusion). Soon after his final echocardiogram. 
this patient had aspiration pneumonitis and multiorgan sys-
tem failure. Two patients had normal right heart size on the 
second follow-up echocardiogram, and two were lost to 
follow-up. On the second follow-up study, right ventricular 
enlargement was found in two patients for the first time. 
Therefore, among the eight patients with right ventricular 
enlargement in Group B, the enlargement had resolved in 
three (38%) on follow-up studies. 
Pericardia I effusion was seen in three patients initially, 
but in only one patient by the time of the first follow-up 
study. On the second follow-up study, one new effusion was 
detected in the patient who developed AIDS. Excluding this 
patient, no association was found between systemic illness 
and pericardial effusion. None of the pericardial effusions 
observed in Group B were clinically or hemodynamically 
significant, and no pericardiocenteses were performed. In 
summary, half of the four effusions seen in Group B had 
resolved by the time of follow-up echocardiograms. 
CD4 counts. In this study, no significant relation was 
found between CD4 counts and left ventricular dysfunction 
or right ventricular enlargement. In Group A, the mean CD4 
count in patients with left ventricular dysfunction was 198 ± 
82/mm3 versus 249 ± 255/mm3 in those with normal left 
ventricular function (p = NS by Fisher's exact test). How-
ever, in Group A patients with echocardiographically proved 
pericardial effusion, CD4 counts (drawn at or near the time 
of echocardiography) were significantly lower (68 ± 74/mm3) 
than in patients without effusion (290 ± 248/mm3, p < 0.001 
by Fisher's exact test). 
Observer variability. Reanalysis was performed of 10% 
of echocardiographic studies chosen at random. Inter- and 
intraobserver variability was < 10% on M-mode measure-
ments and measurement of left ventricular ejection fraction 
and right ventricular end-diastolic area. Observer variability 
was 0% in studies of patients with pericardial effusion. 
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Figure 1. Echocardiographic results for patients in Group A (44 
patients with acquired immunodeficiency syndrome [AIDS] and 6 
with AIDS-related complex). A, Left ventricular (LV) ejection 
fraction at baseline and at first and second follow-up. The cutoff for 
a normal value is depicted by the horizontal line, with all values 
>45% considered normal. B, Right ventricular (RV) areas at base-
line and at first and second follow-up. As depicted by the horizontal 
line, all values <26 cm" are considered normal. 
Discussion 
Cardiac manifestations of AIDS. Recent studies have 
shown that, in addition to the pulmonary, gastrointestinal 
and neurologic complications of AIDS, cardiac manifesta-
tions are not rare, occurring in approximately 40% of pa-
tients (28). Both antemortem and pathologic reports have 
documented a sizable incidence of cardiac abnormalities, 
many of which are asymptomatic or clinically unsuspected at 
the time of discovery. While the prevalence of cardiac 
involvement in AIDS has been studied by several investiga-
tors, there is little information on the evolution of HIV-
associated cardiac disease, particularly in ambulatory pa-
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Figure 2. Echocardiographic results for patients in Group B (20 
patients with asymptomatic human immunodeficiency virus infec-
tion. A, Left ventricular (LV) ejection fraction at baseline and at 1st 
and 2nd follow-up. The cutoff for a normal value is depicted by the 
horizontal line, with all values >45% considered normal. B, Right 
ventricular (RV) areas at baseline and at first and second follow-up. 
As depicted by the horizontal line, all values <26 cm" are considered 
normal. 
tients. Observations on the echocardiographic progression 
of cardiac abnormalities in children have recently been 
published (19), but no such reports are currently available 
for adults. Our prospective study was designed to address 
this issue, 
Fifty patients with AIDS or AIDS-related complex 
(Group A) and 20 patients with asymptomatic HIV infection 
(Group B) were followed up for up to 21 months after 
baseline echocardiography. Overall, 48% of patients had an 
abnormality on one or more echocardiograms. Although 
Group A had a higher percentage of patients with abnormal 
studies (52% vs. 40%), the difference was not statistically 
significant. Fourteen percent of Group A and 5% of Group B 
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Table 2. Previous Studies of Cardiac Function in HIY-Infected Patients 
Author HIV Diagnosis 
% of Patients With Abnormal Echocardiogram 
(reference) (n) Total LV RV PE 
Corallo et al. (6) All AIDS (102)* 54 54 NA 38 
Fink et al. (1) All AIDS (15) 66 20 13 40 
Hecht et al. (9) All AIDS (27) 48 30 NA 26 
Himelman et al. (14) (51 AIDS, 19 HIV +) 27 11 NA 10 
Kinney et al. (22) (15 AIDS, 24 ARC) >47§;>2111 15 NA 31 
Levy et al. (11) (35 AIDS, 25 HIV +) 35 15 NA 30 
Monsuez et al. (7) (43 AIDS, 43 ARC) lOOt; 54+ 33t ; 19+ NA;NA 72t; n 
Raffanti et al. (8) All AIDS (12) 42 17 25 8 
Reitano et al. (21) (21 AIDS, 4 ARC) 40 12 24 28 
Studies are listed alphabetically; the percent of patients with symptoms of heart disease varied from 0% to 14%. *Three of the 102 patients had a cardiac mass; 
tindicates patients with cardiac symptoms; :j:indicates patients without cardiac symptoms: ~of patients with AIDS; Ilof patients with ARC. AIDS'" acquired 
immune deficiency syndrome; ARC '" AIDS-related complex; HIV + '" human immunodeficiency virus infection, without AIDS; LV", left ventricular 
dysfunction/enlargement; NA '" not available; PE '" pericardial effusion; RV = right ventricular enlargement. 
patients had evidence of left ventricular dysfunction (p = 
0.27). The incidence of pericardial effusion and right-sided 
cardiac enlargement was approximately the same in both 
groups, although the only effusions causing hemodynamic 
compromise were seen in Group A. That no patient in either 
group had valvular vegetations may be due in part, to the 
absence of intravenous drug users in the study. Drug users 
were not intentionally excluded from the study. but the great 
majority of patients followed by the California Cooperative 
Treatment Group at this institution are homosexual men 
without a history of drug abuse. Although our patient cohort. 
therefore. does not represent the entire spectrum of individ-
uals with HIV infection, the echocardiographic abnormali-
ties noted may better portray the true effects of HIV 
infection and AIDS, without the confounding influence of 
intravenously injected contaminants, intermittent bactere-
mia and prior episodes of endocarditis. 
Analysis of CD4 counts revealed no association with 
abnormal left ventricular function. However. there was a 
significant correlation between a low CD4 count and the 
presence of a pericardial effusion. 
Comparison with previous reports. Overall. our preva-
lence results are similar to those of previous reports of 
HIV-associated cardiac disease (Table 2). In an echocardio-
graphic study of 102 patients, Corallo et al. (6) reported a 
54% incidence of cardiac abnormalities and left ventricular 
dysfunction. In patients similar to ours (without cardiac 
symptoms at baseline), Monsuez et al. (7) found a 54% 
incidence of abnormalities. including left ventricular dys-
function in 18% and pericardial effusion in 7%. Levy et al. 
(11) reported a 35% incidence of cardiac lesions in a group 
consisting of patients with AIDS and patients with asymp-
tomatic HIV infection. They found a correlation between 
unspecified cardiac abnormalities and low CD4 counts: in 
AIDS patients with CD4 counts < I 00/mm3• the prevalence 
of echocardiographic abnormalities was significantly higher 
(I2 of 22, 55%) than in those with CD4 counts> 100/mm3 (I 
of 14, 7%. P < 0.01) (II). The association between low CD4 
counts and echocardiographic abnormalities was confirmed 
in our study, but only with respect to pericardial effusion. 
The study of Himelman et al. (14) of hospitalized and 
ambulatory HIV -positive patients reported an overall inci-
dence of abnormalities lower than ours; these results may be 
related to the number of echocardiograms performed on 
each study patient-more than 70% of our patients had at 
least two examinations over time, and several patients with 
an initially normal echocardiogram had cardiac abnormali-
ties on follow-up studies. 
While our results confirm those of previous reports. the 
more important aspect of this study is the assessment of the 
evolution of HIV-related cardiac disease. Unexpectedly, a 
number of patients had cardiac abnormalities that were 
transient in nature. In Group A, left ventricular dysfunction 
resolved in 43% of patients by the time of a follow-up 
echocardiogram. as did right-sided cardiac enlargement in 
50% and pericardial effusion in 42%. As stated earlier, no 
patient was limited by congestive heart failure symptoms. as 
such, and none was receiving maintenance treatment with 
digoxin. diuretics or afterioad-reducing agents. No patient in 
either group had symptoms of pericarditis (although two 
patients in Group A had evidence of mild or impending 
tamponade). 
Prognosis of left ventricular dysfunction. Analysis of 
Group A showed that left ventricular dysfunction on a single 
study did not necessarily portend an especially poor prog-
nosis, but a persistently low left ventricular ejection fraction 
(present on two serial echocardiograms) was associated with 
a 100% mortality rate within I year (n = 3). In Group B. the 
only case ofleft ventricular dysfunction at baseline persisted 
on follow-up. and this patient remains alive 18 months later. 
However, by the time of later examination, right ventricular 
enlargement had resolved in 38% of patients and pericardial 
effusion had resolved in 50%. 
It is unlikely that the results presented here are artifac-
tual. A lower than usual abnormal ejection fraction break 
point (45%, the same as that in the study of Himelman, et al. 
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[14]) and a higher than usual abnormal right ventricular 
end-diastolic area (27) were chosen to avoid labeling border-
line results as abnormal. Also, the changes in ejection 
fraction and right ventricular end-diastolic area in those 
patients who crossed the normal/abnormal break points were 
usually not subtle: in Group A, the average change in 
ejection fraction and right ventricular end-diastolic area of 
these patients was 40% and 22%, respectively. Similarly, in 
Group B, the change in right ventricular end-diastolic area 
crossing the same break point was 33%. All values were well 
outside the limits of inter- and intraobserver variability. 
Pathogenesis of cardiac abnormalities. Why, then, are 
cardiac lesions in AIDS occasionally transient? In the case 
of left ventricular dysfunction, several possibilities exist. 
Recent studies (3.4,1 3,17) support infectious myocarditis as 
the probable cause of left ventricular dysfunction in patients 
with AIDS. Several viruses that are known to cause cardio-
myopathies in humans may be transient, and a case of 
coxsackie virus B myocarditis in a patient with HIY with left 
ventricular enlargement was recently described (29). 
It is also possible that HIV itself is cardiomyopathic. An 
intriguing possibility, therefore, is that AZT may improve 
left ventricular function in cases of HIY-associated cardio-
myopathy. Indeed, all three patients with abnormal left 
ventricular ejection fraction in Group A who showed im-
provement on the first follow-up echocardiogram were tak-
ing AZT. However, the three patients whose left ventricular 
function did not improve from baseline (and the patient 
whose left ventricular function was depressed on the second 
follow-up examination) were taking AZT as well. Thus, our 
data are not sufficient to support AZT as an effective therapy 
for HIV-associated cardiomyopathy. Two other drugs com-
monly used in AIDS patients, co-trimoxazole and pentami-
dine, are not known to cause left ventricular enlargement or 
myocarditis, although the latter drug has been reported to 
cause prolongation of the QT interval and torsade de pointes 
(30). Zazzo et al. (31) have theorized that nutritional defi-
ciencies may be linked to cardiomyopathy in AIDS. Al-
though these may have contributed to the abnormalities 
seen, the close medical follow-up of our patients makes 
severe nutritional deficiencies somewhat unlikely. 
Right-sided cardiac enlargement occurred along with left 
ventricular enlargement or hypertrophy in 33% of all cases, 
and of these. only one resolved (coincident with an improve-
ment in left ventricular function). A possible explanation for 
episodic, isolated right ventricular enlargement in our AIDS 
patients is pulmonary hypertension secondary to pneumonia 
and hypoxia. Although this study was not designed to 
specifically address right ventricular size before and after 
pneumonia, it is logical that successful treatment of pulmo-
nary infections and reversal of hypoxia could decrease right 
ventricular afterload and normalize right ventricular size. 
Although four patients with AIDS were diagnosed with 
Pneumocystis carinii pneumonia near the time of an 
echocardiogram that showed right ventricular enlargement, 
the majority of patients had no evidence of a recent or 
intercurrent pulmonary illness. Thus, hypoxia and pulmo-
nary disease may account for some but not all cases of right 
ventricular enlargement in AIDS. Interstitial and restrictive 
lung disease as well as primary pulmonary hypertension 
have been observed (32,33) in patients with AIDS who have 
right ventricular enlargement and elevated pulmonary artery 
pressure. Although this type of lung disease may be respon-
sible for some cases of right ventricular enlargement in our 
study, it is unlikely to have been present in all patients with 
transient right-sided cardiac abnormalities. 
Opportunistic pulmonary infections did not occur in 
Group B patients (except in the one patient who developed 
AIDS during the study period). and the cases of transient, 
isolated right ventricular enlargement in this group are more 
difficult to explain. These patients may have had subclinical 
episodes of pulmonary disease, but the origin of right-sided 
cardiac abnormalities in this group is unclear and requires 
further study. 
Infectious myocarditis and pericarditis probably account 
for a number of cases of transient pericardial effusion in our 
patients; hypoalbuminemia and contiguous pneumonic pro-
cesses also may have played a role. No patient had radiation 
to the chest or had evidence of ischemic heart disease or 
myocardial infarction. Two cases of effusion in Group A and 
one in Group B occurred in the presence of left ventricular 
enlargement and dysfunction. Effusions were either small or 
moderate in size in all but two patients (in Group A), who 
had a large effusion and evidence of tamponade. 
Limitations. There are several limitations to this study. 
First. follow-up is incomplete, typically because death oc-
curred before follow-up echocardiography was performed 
(Group A), and contact was lost with patients (Group B). 
Follow-up examinations were scheduled at the beginning of 
the study to be conducted at least 6 months apart; therefore, 
several cases of cardiac abnormalities may have been missed 
in those patients who died just before follow-up echocardio-
grams were obtained. These limitations to follow-up may 
bias the results toward an underestimation of cardiac le-
sions. Second, the present study was not designed to include 
pathologic and autopsy correlation with echocardiographic 
findings; therefore, it is not possible to correlate antemortem 
echocardiographic manifestations with pathologically docu-
mented myocarditis, myocardial fibrosis, valvular lesions 
and ventricular enlargement. Although several pathologic 
reports are available (2,3.4.13.15) of AIDS and cardiac 
complications, this area merits further investigation. 
Finally, as in all echocardiographic studies, intra- and 
interobserver variability may limit the reliability of our data. 
However, observer variability of ejection fraction and right 
ventricular end-diastolic area calculations was low «10%), 
and nonexistent in cases of pericardial effusion. In addition, 
in those patients whose left ventricular ejection fraction or 
right ventricular size became normal or abnormal. the 
changes were rarely subtle. with mean differences substan-
tially greater than the observer variability. 
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Clinical implications. Our study has several implications. 
First, although there are no truly "good" prognostic mark-
ers in this debilitating and ultimately fatal disease, the 
presence of left ventricular enlargement or dysfunction on a 
single echocardiogram may not be as ominous as previously 
thought, because the condition of some patients may im-
prove over time. Therefore, a single low ejection fraction 
does not imply that further intervention will be completely 
unsuccessful. Second, because many abnormalities detected 
in our patients were not clinically suspected, we agree with 
Himelman et al. (14) that echocardiography should be con-
sidered early in patients with HIY infection who have 
dyspnea or vague chest complaints. Finally, it is unclear 
whether HIY itself is a cardiomyopathic agent, and our 
study does not lend support to either side of the debate. Our 
finding of transient cardiac abnormalities, however, has 
important implications for future studies involving therapy 
for AIDS-associated heart disease. 
We thank Linda Donaghey and Karen Wheeler for their superb technical 
support, and the staff of the California Cooperative Treatment Group at the 
University of California, San Diego for their invaluable assistance. 
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